Elman Retina Group has a long and distinguished history as one of the premier clinical trial sites in the Mid-Atlantic region. Our participation in landmark studies has contributed directly to the development of FDA-approved treatments that are now the standard of care for retinal diseases.
Why Clinical Trials Matter
Clinical trials are the engine of medical progress. They give patients access to promising new therapies — often years before they become widely available — while advancing scientific understanding of retinal diseases.
Our Research Legacy
Over the past three decades, Elman Retina Group has participated in many of the most important retinal studies, including:
- The DRCR Retina Network studies on diabetic retinopathy treatment
- Pivotal trials leading to the approval of major anti-VEGF medications
- Studies evaluating next-generation drug delivery systems
- Research into gene therapy for inherited retinal diseases
Eligibility for Current Studies
We are currently enrolling patients in studies related to age-related macular degeneration, diabetic macular edema, and other retinal conditions. If you're interested in learning whether you may qualify for a clinical trial, contact our research team at 410-686-3000.
Participation in clinical trials is always voluntary, and our team will thoroughly explain all aspects of any study before you make a decision.
